<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
                      "http://www.w3.org/TR/html4/strict.dtd">
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<meta name="generator" content="hypermail 2.1.5, see http://www.hypermail.org/">
<title>Extropians: RE: Performance enhancement with selegiline</title>
<meta name="Author" content="Rafal Smigrodzki (rms2g@virginia.edu)">
<meta name="Subject" content="RE: Performance enhancement with selegiline">
<meta name="Date" content="2003-02-13">
<style type="text/css">
body {color: black; background: #ffffff}
h1.center {text-align: center}
div.center {text-align: center}
</style>
</head>
<body>
<h1>RE: Performance enhancement with selegiline</h1>
<!-- received="Thu Feb 13 12:48:16 2003" -->
<!-- isoreceived="20030213194816" -->
<!-- sent="Thu, 13 Feb 2003 14:55:26 -0500" -->
<!-- isosent="20030213195526" -->
<!-- name="Rafal Smigrodzki" -->
<!-- email="rms2g@virginia.edu" -->
<!-- subject="RE: Performance enhancement with selegiline" -->
<!-- id="BMEDJIBJGLNDOOANGIDLCEOACJAA.rms2g@virginia.edu" -->
<!-- charset="iso-8859-1" -->
<!-- inreplyto="019c01c2cf6d$065035a0$e35f87d8@pavilion" -->
<!-- expires="-1" -->
<p>
<strong>From:</strong> Rafal Smigrodzki (<a href="mailto:rms2g@virginia.edu?Subject=RE:%20Performance%20enhancement%20with%20selegiline"><em>rms2g@virginia.edu</em></a>)<br>
<strong>Date:</strong> Thu Feb 13 2003 - 12:55:26 MST
</p>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2665.html">EvMick@aol.com: "Media Bias"</a>
<ul>
<li><strong>Previous message:</strong> <a href="2663.html">EvMick@aol.com: "Re: taxing solar power"</a>
<li><strong>In reply to:</strong> <a href="2315.html">gts: "Re: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2788.html">gts: "RE: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2788.html">gts: "RE: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2664">[ date ]</a>
<a href="index.html#2664">[ thread ]</a>
<a href="subject.html#2664">[ subject ]</a>
<a href="author.html#2664">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<hr>
<!-- body="start" -->
<p>
gts wrote:
<br>
<p><em>&gt; Here is published evidence that selegiline (deprenyl) increases
</em><br>
<em>&gt; life-expectancy in Parkinson's Disease, (something that Rafal
</em><br>
<em>&gt; considers impossible.)
</em><br>
<p>### So, finally I had the time to look at the article.
<br>
<p>It turns out to be an open, uncontrolled study, which according to the AAN
<br>
Practice Guidelines is class IV evidence (meaning - hardly any evidence at
<br>
all). In the presence of class II studies, such as DATATOP, this can be
<br>
discarded as worthless.
<br>
<p>See <a href="http://www.aan.com/professionals/practice/pdfs/int_par.pdf">http://www.aan.com/professionals/practice/pdfs/int_par.pdf</a>
<br>
<p>---------
<br>
<em>&gt;
</em><br>
<em>&gt; In this 9 year study, 564 of  941 PD patients were given selegiline
</em><br>
<em>&gt; as part of their treatment. The patients treated with selegiline
</em><br>
<em>&gt; lived significantly longer than those not treated with selegiline.
</em><br>
<em>&gt; This is strong evidence that selegiline actually slows the
</em><br>
<em>&gt; progression of the disease in addition to relieving its symptoms.
</em><br>
<p>### It is not evidence of anything at all. The results of open, uncontrolled
<br>
studies are subject to so many sources of bias that all they are good for is
<br>
suggesting additional research, which in this case flatly refuted the
<br>
conclusion of this study.
<br>
<p>Rafal
<br>
<p><em>&gt;
</em><br>
<em>&gt; ABSTRACT
</em><br>
<em>&gt; Increased life expectancy resulting from addition of L-deprenyl to
</em><br>
<em>&gt; Madopar treatment in Parkinson's disease: a longterm study.
</em><br>
<em>&gt;
</em><br>
<em>&gt; J Neural Transm 1985;64(2):113-27    (ISSN: 0300-9564)
</em><br>
<em>&gt; Birkmayer W; Knoll J; Riederer P; Youdim MB; Hars V; Marton J
</em><br>
<em>&gt; In an open, uncontrolled study the longterm (9 years) effect of
</em><br>
<em>&gt; treatment with Madopar alone (n = 377) or in combination with
</em><br>
<em>&gt; l-deprenyl (selegiline, selective monoamine oxidase type B inhibitor)
</em><br>
<em>&gt; (n = 564) have been compared in Parkinsonian patients. In patients
</em><br>
<em>&gt; who lost their response to conventional Madopar therapy the addition
</em><br>
<em>&gt; of l-deprenyl resulted in a significant recouping of levodopa effect.
</em><br>
<em>&gt; The survival analysis revealed a significant increase of life
</em><br>
<em>&gt; expectancy in Madopar--l-deprenyl group regardless of the fact
</em><br>
<em>&gt; whether or not the significant demographic differences between the
</em><br>
<em>&gt; two groups were taken into account. Although the mechanism underlying
</em><br>
<em>&gt; this action of l-deprenyl is not known, the results are interpreted
</em><br>
<em>&gt; as indicating l-deprenyl's ability to prevent or retard the
</em><br>
<em>&gt; degeneration of striatal dopaminergic neurons. l-Deprenyl is the
</em><br>
<em>&gt; first anti-Parkinson drug having such a property. This hypothesis is
</em><br>
<em>&gt; not far fetched since l-deprenyl selectively prevents the
</em><br>
<em>&gt; degeneration of striatal dopaminergic neurons induced in animals by
</em><br>
<em>&gt; the illicit drug 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
</em><br>
<em>&gt; Since latter compound is known to cause Parkinsonism in man and
</em><br>
<em>&gt; primates or Parkinson-like neurochemical and pathological changes in
</em><br>
<em>&gt; other animals the implications of the present study involving
</em><br>
<em>&gt; monoamine oxidase activity and l-deprenyl are apparent.
</em><br>
<!-- body="end" -->
<hr>
<ul>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2665.html">EvMick@aol.com: "Media Bias"</a>
<li><strong>Previous message:</strong> <a href="2663.html">EvMick@aol.com: "Re: taxing solar power"</a>
<li><strong>In reply to:</strong> <a href="2315.html">gts: "Re: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2788.html">gts: "RE: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2788.html">gts: "RE: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2664">[ date ]</a>
<a href="index.html#2664">[ thread ]</a>
<a href="subject.html#2664">[ subject ]</a>
<a href="author.html#2664">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<!-- trailer="footer" -->
<hr>
<p><small><em>
This archive was generated by <a href="http://www.hypermail.org/">hypermail 2.1.5</a> 
: Thu Feb 13 2003 - 12:50:30 MST
</em></small></p>
</body>
</html>
